Cargando…
Cost-effectiveness of programmed cell death ligand 1 testing and tumor mutational burden testing of immune checkpoint inhibitors for advanced non-small cell lung cancer
Autores principales: | Li, Wen-Qian, Li, Ling-Yu, Bai, Ri-Lan, Qian, Lei, Chen, Nai-Fei, Cui, Jiu-Wei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7722558/ https://www.ncbi.nlm.nih.gov/pubmed/33009031 http://dx.doi.org/10.1097/CM9.0000000000001120 |
Ejemplares similares
-
Efficacy of cell-free DNA methylation-based blood test for colorectal cancer screening in high-risk population: a prospective cohort study
por: Zhao, Fuqiang, et al.
Publicado: (2023) -
Subungual squamous cell carcinoma treated by topical photodynamic therapy
por: An, Qian, et al.
Publicado: (2020) -
A brand new era of cancer immunotherapy: breakthroughs and challenges
por: Bai, Ri-Lan, et al.
Publicado: (2021) -
Cell Block as a Surrogate for Programmed Death-Ligand 1 Staining Testing in Patients of Non-Small Cell Lung Cancer
por: Dong, Zhengwei, et al.
Publicado: (2020) -
‘Test, re-test, re-test’: using inaccurate tests to greatly increase the accuracy of COVID-19 testing
por: Ramdas, Kamalini, et al.
Publicado: (2020)